Two drugs now dominate the GLP-1 weight loss landscape: tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for obesity) and semaglutide (Ozempic for diabetes, Wegovy for obesity). Both belong to the GLP-1 receptor agonist class, both require weekly injections, and both produce weight loss that was previously unachievable without surgery. But they are not identical — in mechanism, in clinical outcomes, or in the populations they benefit most.
This guide walks through the 2026 evidence in plain language, so you can have a genuinely informed conversation with your prescriber.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. It was approved by the FDA for type 2 diabetes (Mounjaro) in May 2022 and for chronic weight management (Zepbound) in November 2023. In clinical trials it has consistently produced the largest average weight loss ever recorded for a pharmacological agent.
Semaglutide is a selective GLP-1 receptor agonist developed by Novo Nordisk. Ozempic received FDA approval for type 2 diabetes in 2017; Wegovy — at the higher 2.4 mg weekly dose — was approved for obesity in 2021. Semaglutide also has robust cardiovascular outcome data that tirzepatide is still accumulating.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Brand names | Mounjaro (T2D), Zepbound (obesity) | Ozempic (T2D), Wegovy (obesity) |
| Mechanism | Dual GIP + GLP-1 receptor agonist | Selective GLP-1 receptor agonist |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Starting dose | 2.5 mg/week | 0.25 mg/week (both Ozempic and Wegovy) |
| Maximum dose | 15 mg/week | 2 mg/week (Ozempic) / 2.4 mg/week (Wegovy) |
| Avg weight loss (obesity trial) | ~22.5% body weight (SURMOUNT-1, 72 wk) | ~14.9% body weight (STEP-1, 68 wk) |
| FDA approval: T2D | Yes (Mounjaro, 2022) | Yes (Ozempic, 2017) |
| FDA approval: Obesity | Yes (Zepbound, Nov 2023) | Yes (Wegovy, Jun 2021) |
| Cardiovascular outcomes trial | SURMOUNT-MMO (ongoing/emerging) | SELECT trial (2023) — positive results |
| Estimated monthly cost (no insurance) | ~$1,060–$1,400/month | ~$900–$1,350/month |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Pen device | KwikPen (single-dose) | FlexTouch / autoinjector pen |
| Compounding availability | Tirzepatide base compounds available (supply-dependent) | Semaglutide compounds available; FDA has issued warnings |
Both drugs activate the glucagon-like peptide-1 (GLP-1) receptor. When this receptor fires, it triggers a cascade of metabolic effects: the pancreas releases more insulin in a glucose-dependent manner (so hypoglycemia risk is low), glucagon secretion is suppressed, and gastric emptying slows dramatically. That last effect is what produces the profound satiety and reduced appetite both drugs are famous for. The brain's hypothalamus also has GLP-1 receptors, and direct central action appears to reduce food-seeking behavior and caloric reward.
Semaglutide's entire pharmacological effect flows through this single receptor. It is an exceptionally potent and long-acting GLP-1 agonist — its 94% structural homology with human GLP-1, combined with fatty acid albumin binding, gives it a half-life of approximately seven days, enabling once-weekly dosing.
Tirzepatide adds agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor, making it a dual incretin receptor agonist. GIP is the other major incretin hormone, released from K-cells in the small intestine after eating. Historically it was thought to be a less important incretin — people with type 2 diabetes often show GIP resistance. Tirzepatide's developers at Lilly found that pharmacological GIP receptor activation, at higher-than-physiological levels, actually restores GIP signaling and powerfully potentiates the GLP-1 response.
The adipose tissue implications of dual agonism are significant. GIP receptors are expressed on fat cells, and GIP agonism appears to increase lipolysis (fat breakdown) and alter energy partitioning in adipose tissue in ways that GLP-1 agonism alone does not. Pre-clinical and emerging clinical data suggest tirzepatide promotes preferential loss of fat mass while preserving lean mass better than single-agonist approaches — though head-to-head data on body composition specifically are still accumulating.
Key insight: Tirzepatide is not simply "a stronger semaglutide." It works through an additional receptor pathway that produces synergistic metabolic effects. The ~7.5 percentage point difference in average weight loss between the two drugs is biologically meaningful, not just a dosing artifact.
Both drugs meaningfully improve insulin sensitivity. The SURPASS trials showed tirzepatide produced HbA1c reductions of up to 2.58% at the 15 mg dose. Semaglutide at 2 mg achieved HbA1c reductions of approximately 2.2% across the SUSTAIN and related trials. For people with type 2 diabetes, both are among the most effective non-insulin glucose-lowering agents available.
Population: 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes.
Duration: 72 weeks
Results: Participants randomized to tirzepatide 15 mg lost an average of 22.5% of body weight — approximately 52 lbs (23.6 kg) from a mean starting weight of ~231 lbs. At the 10 mg dose, average loss was 21.4%; at 5 mg, 16.0%. Nearly 57% of participants on the 15 mg dose achieved ≥20% weight loss. Placebo arm lost 2.4%.
Published: New England Journal of Medicine, 2022
Population: 1,961 adults with obesity or overweight with comorbidities, without type 2 diabetes.
Duration: 68 weeks
Results: Participants on semaglutide 2.4 mg lost an average of 14.9% of body weight (~34 lbs / 15.3 kg). Approximately 35% achieved ≥15% weight loss, and about 10% achieved ≥20%. Placebo arm lost 2.4%.
Published: New England Journal of Medicine, 2021
The SURPASS trials (SURPASS-1 through SURPASS-6) enrolled people with type 2 diabetes. Across doses, tirzepatide produced HbA1c reductions of 1.87–2.58% and weight loss of 7–13 kg, consistently outperforming comparator agents including insulin degludec, insulin glargine, and — critically — semaglutide 1 mg (see SURPASS-2 below).
The SUSTAIN series established semaglutide's efficacy in type 2 diabetes, including SUSTAIN-6 which demonstrated cardiovascular risk reduction. Semaglutide 0.5 mg and 1 mg produced HbA1c reductions of ~1.4–1.8% and weight loss of 4–6 kg across this population.
It is important to note that SURMOUNT-1 and STEP-1 cannot be directly compared as definitive proof that tirzepatide is superior to semaglutide in all individuals. The trials differed in duration, population characteristics, and design elements. A true randomized head-to-head in an obesity population remains the gold standard — and while observational and network meta-analysis data consistently favor tirzepatide, this distinction matters.
SURPASS-2 is the closest thing we have to a direct head-to-head trial, though it comes with an important caveat. The trial enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin and randomized them to tirzepatide (5 mg, 10 mg, or 15 mg) versus semaglutide 1 mg — the standard diabetes dose, not the 2.4 mg Wegovy obesity dose.
| Treatment Arm | HbA1c Reduction | Body Weight Reduction |
|---|---|---|
| Tirzepatide 5 mg | −2.01% | −7.6 kg (−8.0%) |
| Tirzepatide 10 mg | −2.24% | −9.3 kg (−9.8%) |
| Tirzepatide 15 mg | −2.30% | −11.2 kg (−11.9%) |
| Semaglutide 1 mg | −1.86% | −5.7 kg (−6.2%) |
All three tirzepatide doses achieved statistically superior HbA1c reduction and weight loss versus semaglutide 1 mg. However, semaglutide 1 mg for diabetes is roughly equivalent to Ozempic — not Wegovy (2.4 mg). This means SURPASS-2 is not a fair comparison for obesity treatment, where semaglutide 2.4 mg would be expected to produce meaningfully greater weight loss.
Network meta-analyses and real-world observational data published through 2025–2026 consistently show tirzepatide achieving greater weight loss at comparable treatment durations, but the magnitude of the advantage narrows somewhat when semaglutide 2.4 mg is the comparator. A true head-to-head RCT in an obesity-primary population is highly anticipated.
Both tirzepatide and semaglutide share a class-wide GI side effect profile. Because both slow gastric emptying substantially, nausea, vomiting, diarrhea, and constipation are the most common adverse events — and the primary driver of discontinuation in clinical trials.
| Side Effect | Tirzepatide (SURMOUNT-1) | Semaglutide (STEP-1) |
|---|---|---|
| Nausea (any severity) | ~33–42% | ~44% |
| Diarrhea | ~22–30% | ~30% |
| Vomiting | ~17–24% | ~24% |
| Constipation | ~20–24% | ~24% |
| Injection site reactions | Slightly higher (~3–5%) | ~0.8–1.5% |
| Discontinuation due to AEs | ~4.3–6.2% | ~4.5–7.0% |
| Serious GI events | Rare (<1%) | Rare (<1%) |
The slow dose-escalation schedule (starting at 2.5 mg tirzepatide or 0.25 mg semaglutide, titrating over weeks to months) is specifically designed to allow GI tolerance to develop. Most people who experience significant nausea do so during the titration phase; it typically improves or resolves once a maintenance dose is reached. Eating smaller meals, avoiding high-fat and high-sugar foods, and staying hydrated significantly reduce symptom burden for most patients.
This is the area where semaglutide's longer track record becomes genuinely important.
Published in the New England Journal of Medicine in November 2023, SELECT enrolled 17,604 adults with established cardiovascular disease, a BMI ≥27, and no diabetes. Participants received either semaglutide 2.4 mg (Wegovy) or placebo weekly for a median of 34 months.
Result: Semaglutide reduced the risk of major adverse cardiovascular events (MACE — cardiovascular death, non-fatal MI, or non-fatal stroke) by 20% (HR 0.80; 95% CI 0.72–0.90; p<0.001). This was the first trial to demonstrate cardiovascular risk reduction with a GLP-1 agonist in a non-diabetic population.
This data led to an FDA label expansion for Wegovy to include cardiovascular risk reduction as an indication — a historic milestone for the obesity treatment field.
Tirzepatide does not yet have equivalent published cardiovascular outcome data. The SURMOUNT-MMO trial is ongoing and will evaluate cardiovascular endpoints in people with obesity. Until those results are available, clinicians managing patients with high cardiovascular risk may reasonably prefer semaglutide based on the established SELECT data.
Importantly, tirzepatide's SURPASS trials did include cardiovascular safety data and found no increase in cardiovascular events — but a dedicated outcomes trial powering for MACE reduction is what the field is waiting for.
Both drugs are expensive without insurance coverage. As of mid-2026:
Eli Lilly's Lilly Cares savings card for Zepbound has allowed commercially insured patients to pay as little as $25–$550/month, though eligibility requirements and caps apply. Novo Nordisk offers similar programs for Wegovy and Ozempic. These programs are generally not available to Medicare or Medicaid patients.
| Drug | Medicare Part D | Commercial Insurance | Medicaid |
|---|---|---|---|
| Zepbound (obesity) | Now covered under expanded Medicare obesity benefit (2024–2026 expansion) | Variable; coverage growing rapidly post-SELECT and post-Zepbound approval | State-dependent; improving |
| Wegovy (obesity) | Covered for cardiovascular risk reduction indication (SELECT label) | Growing coverage; most major PBMs now include | Limited but expanding |
| Mounjaro/Ozempic (diabetes) | Covered as diabetes medications | Generally covered as T2D treatments | Generally covered |
Medicare note: CMS expanded coverage of Zepbound for obesity in stages beginning in 2024. Medicare beneficiaries with obesity (BMI ≥30) or overweight (BMI ≥27) plus a weight-related comorbidity may now be eligible. Check with your Part D plan for current formulary status.
Both tirzepatide and semaglutide are available via telehealth prescription platforms in the United States. This has dramatically expanded access, particularly for people without an endocrinologist or obesity medicine specialist nearby.
Major platforms as of 2026 include Hims & Hers, WeightWatchers Clinic, Ro Body, Form Health, and Found. Several of these platforms offer compounded versions of semaglutide or tirzepatide at lower price points — however, these are not FDA-approved products and the FDA has issued warnings about compounded semaglutide in particular. Supply constraints on brand-name medications have eased significantly in 2025–2026 compared to the severe shortages of 2023–2024.
When using telehealth for GLP-1 medications:
This is a decision to make with your physician or obesity medicine specialist. That said, the clinical data points to some general patterns:
This is the most important long-range question. The STEP-4 trial (semaglutide withdrawal) showed participants regained approximately two-thirds of their lost weight within one year of stopping. Similar patterns are seen with tirzepatide withdrawal. Both drugs appear to treat obesity rather than cure it — the underlying metabolic setpoint reasserts when medication is withdrawn. This argues for thinking of GLP-1 therapy as a long-term or chronic treatment, similar to how one would approach antihypertensives or statins.
Tirzepatide produces greater weight loss on average — approximately 20–22% of body weight versus approximately 15% for semaglutide, based on the best available trial data. That difference is clinically meaningful: for a 250 lb person, it is the difference between losing roughly 37 lbs and losing roughly 55 lbs. If your primary goal is maximum weight loss, tirzepatide currently has an edge.
Semaglutide has more robust cardiovascular outcome data. The SELECT trial established a 20% relative reduction in major cardiovascular events in non-diabetic people with obesity and established heart disease — data that tirzepatide does not yet have. For patients with CVD as a co-primary concern, this matters.
Both are transformative medications. Either drug, taken consistently with appropriate lifestyle support, produces weight loss that changes metabolic risk profiles, improves quality of life, and in many cases reduces or eliminates the need for other medications (antihypertensives, statins, diabetes drugs). The decision between them should be driven by your individual clinical profile, cardiovascular risk, insurance coverage, and — frankly — which drug you and your prescriber can access affordably and maintain long-term.
The ideal head-to-head trial comparing tirzepatide vs semaglutide 2.4 mg in obesity is still awaited. Until it arrives, use the data above as a framework, not a final verdict.